Company intelligence / Profile preview
CANbridge Pharmaceuticals Inc.
Beijing, Beijing, Chinacanbridgepharma.com ↗
- Ownership
- Public · 1228.HK
- Employees
- ~67
- Development stage
- Commercial
01
Overview
CANbridge has 3 approved drugs and is developing multiple candidates for rare diseases. Their CAN103 for Gaucher disease has completed a pivotal trial with positive results and has received priority review status from China's NMPA with expected launch in 2025. They have successfully commercialized Hunterase for Hunter syndrome and Livmarli for cholestatic pruritus in patients with Alagille syndrome in China, Hong Kong, and Taiwan.
- Therapeutic areas
- GastroenterologyOncologyImmunologyHematologyRare DiseasesNeurology
- Modalities
- Enzyme Replacement Therapy (ERT)Monoclonal AntibodiesGene TherapySmall Molecules
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →03
Partnerships
ApogenixGC Biopharma/GC PharmaMirum PharmaceuticalsWuXi BiologicsPrivus BiologicsUMass Chan Medical SchoolUniversity of Washington School of MedicineScriptr Global
Beyond the preview
Go deeper on CANbridge Pharmaceuticals Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CANbridge Pharmaceuticals Inc..